vida: extract claims from 2026-04-22-kff-medicare-glp1-bridge-lis-exclusion

- Source: inbox/queue/2026-04-22-kff-medicare-glp1-bridge-lis-exclusion.md
- Domain: health
- Claims: 2, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Even government-designed coverage expansions can structurally exclude the most vulnerable populations through legal architecture choices that override equity intentions
+confidence: experimental
+source: KFF analysis of Medicare GLP-1 Bridge program structure (April 2026)
+created: 2026-04-22
+title: Federal GLP-1 expansion programs reproduce the access hierarchy at the program design level, not just through market dynamics
+agent: vida
+sourced_from: health/2026-04-22-kff-medicare-glp1-bridge-lis-exclusion.md
+scope: structural
+sourcer: KFF Health Policy
+related: ["generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost"]
+---
+
+# Federal GLP-1 expansion programs reproduce the access hierarchy at the program design level, not just through market dynamics
+
+The Medicare GLP-1 Bridge program demonstrates that the GLP-1 access inversion operates at the program design level, not just the market level. While the program was designed to 'expand access' to GLP-1 obesity medications, its legal architecture—required because Medicare is statutorily prohibited from covering weight-loss drugs—places it outside standard Part D benefit structures. This design choice has the consequence of making Low-Income Subsidy (LIS) protections inapplicable, creating a $50 copay barrier for the lowest-income beneficiaries. The mechanism is not market failure or insurance company gatekeeping, but federal program architecture itself. The program's eligibility criteria are inclusive (BMI ≥35 alone, or ≥27 with clinical criteria), but the cost-sharing structure excludes the most access-constrained population. This reveals that access inversions can be encoded into the legal and administrative structure of interventions designed to improve equity, suggesting that coverage expansion and coverage restriction can occur simultaneously through different layers of program design. The pattern indicates that addressing GLP-1 access disparities requires attention to program architecture, not just coverage mandates.

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -32,3 +32,10 @@ Nearly 4 in 10 adults and a quarter of children with Medicaid have obesity, repr
 **Source:** KFF Medicaid GLP-1 Coverage Analysis, January 2026
 
 The Medicaid population has the highest obesity burden (40% of adults, 25% of children) but only 26% of state programs provide coverage. Even where covered, GLP-1s are 'typically subject to utilization controls such as prior authorization,' creating additional access barriers for the population with least ability to pay out of pocket.
+
+
+## Extending Evidence
+
+**Source:** KFF analysis of Medicare GLP-1 Bridge program (April 2026)
+
+The Medicare GLP-1 Bridge program provides concrete evidence that the access inversion operates through federal program architecture, not just market dynamics. The program's legal structure—required because Medicare is statutorily prohibited from covering weight-loss drugs—places the benefit outside Part D cost-sharing structures, making Low-Income Subsidy (LIS) protections inapplicable. This creates a $50 copay barrier for the lowest-income beneficiaries despite inclusive eligibility criteria. The mechanism is program design itself: coverage expansion and coverage restriction occurring simultaneously through different layers of administrative architecture.

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -25,3 +25,10 @@ States with the highest obesity rates (Mississippi, West Virginia, Louisiana at
 **Source:** KFF Medicaid GLP-1 Coverage Analysis, January 2026
 
 As of January 2026, only 13 states (26% of state programs) cover GLP-1s for obesity under fee-for-service Medicaid, despite nearly 40% of adults and 25% of children with Medicaid having obesity. This represents tens of millions of potentially eligible beneficiaries without coverage, creating a geographic lottery where eligibility depends on state of residence more than clinical need.
+
+
+## Extending Evidence
+
+**Source:** KFF analysis of Medicare GLP-1 Bridge program (April 2026)
+
+The Medicare GLP-1 Bridge program demonstrates that access inversion operates at the federal program design level, not just state-level coverage decisions. The program's LIS exclusion means that even a federal coverage expansion structurally excludes the lowest-income Medicare beneficiaries, adding a new layer to the systematic inversion pattern: legal architecture can override equity intentions.

domains/health/medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The program's legal architecture places the $50 copay outside Part D cost-sharing structures, making it invisible to LIS subsidies and creating a real barrier for the most access-constrained population
+confidence: experimental
+source: KFF Health Policy analysis of CMS Medicare GLP-1 Bridge program documents (April 2026)
+created: 2026-04-22
+title: The Medicare GLP-1 Bridge program's Low-Income Subsidy exclusion structurally denies the lowest-income Medicare beneficiaries access to GLP-1 obesity coverage despite nominal eligibility
+agent: vida
+sourced_from: health/2026-04-22-kff-medicare-glp1-bridge-lis-exclusion.md
+scope: structural
+sourcer: KFF Health Policy
+supports: ["glp-1-access-structure-inverts-need-creating-equity-paradox"]
+related: ["medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi"]
+---
+
+# The Medicare GLP-1 Bridge program's Low-Income Subsidy exclusion structurally denies the lowest-income Medicare beneficiaries access to GLP-1 obesity coverage despite nominal eligibility
+
+The Medicare GLP-1 Bridge program (July-December 2026) covers Wegovy and Zepbound at a fixed $50 copayment for eligible Part D beneficiaries. However, the program contains a critical structural flaw: Low-Income Subsidy (LIS) cost-sharing subsidies will not apply to GLP-1 prescriptions filled under this program. This means the $50 copay represents a real out-of-pocket barrier for the very beneficiaries who most rely on the LIS to afford medications. The copay was specifically designed to fall outside standard Part D cost-sharing structures—it does not count toward the Part D deductible or the $2,100 out-of-pocket cap. This isn't an oversight but reflects the novel legal architecture of the program, which operates 'outside' Part D benefit structures because Medicare is statutorily prohibited from covering weight-loss drugs. The result is that the benefit's eligibility criteria say 'yes' to low-income patients while the cost-sharing architecture says 'no.' This creates a segregated benefit structure where federal GLP-1 expansion specifically fails the lowest-income Medicare population—the inverse of what a functional access intervention would do. KFF notes that advocates are flagging this issue but no fix has been announced.

entities/health/medicare-glp1-bridge-program.md

@@ -0,0 +1,52 @@
+---
+type: entity
+entity_type: research_program
+name: Medicare GLP-1 Bridge Program
+domain: health
+status: active
+start_date: 2026-07-01
+end_date: 2026-12-31
+parent_organization: Centers for Medicare & Medicaid Services (CMS)
+---
+
+# Medicare GLP-1 Bridge Program
+
+A temporary demonstration program providing Medicare Part D coverage for GLP-1 receptor agonists (Wegovy and Zepbound) for obesity treatment from July 1 to December 31, 2026.
+
+## Program Structure
+
+**Eligibility:**
+- BMI ≥35 alone, or ≥27 with clinical criteria
+- Must be enrolled in Medicare Part D
+- Estimated ~14 million Medicare beneficiaries had diagnosed overweight/obesity in 2020 (potential eligible pool)
+
+**Cost-sharing:**
+- Fixed $50 copayment per prescription
+- Copay does NOT count toward Part D deductible or $2,100 out-of-pocket cap
+- Low-Income Subsidy (LIS) cost-sharing subsidies do NOT apply to prescriptions filled under this program
+
+**Legal Architecture:**
+- Operates outside standard Part D benefit structures because Medicare is statutorily prohibited from covering weight-loss drugs
+- Requires CMS demonstration authority, not legislative change
+- Temporary exception, not durable coverage
+
+## Structural Issues
+
+The program's placement outside Part D cost-sharing structures makes Low-Income Subsidy (LIS) protections inapplicable, creating a $50 copay barrier for the lowest-income beneficiaries despite inclusive eligibility criteria. This represents a structural misalignment where coverage expansion and coverage restriction occur simultaneously through different layers of program design.
+
+## Relationship to Other Programs
+
+- **BALANCE Model (Medicare Part D):** Longer demonstration launching January 2027
+- **BALANCE Model (Medicaid):** Begins May 2026
+- Beneficiaries seeking continued coverage in 2027 may need to switch Part D plans during open enrollment
+
+## Timeline
+
+- **2026-04** — Program details announced by CMS
+- **2026-07-01** — Program begins
+- **2026-12-31** — Program ends
+
+## Sources
+
+- KFF Health Policy analysis (April 2026)
+- CMS program documents